Clonotypic VDJ Rearrangements in Mixed Phenotype Acute Leukemia can be Successfully Utilized to Track Minimal Residual Disease
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Next-generation sequencing (NGS) effectively tracks minimal residual disease (MRD) in mixed phenotype acute leukemia (MPAL). This sensitive method shows promise for improved patient monitoring compared to traditional flow cytometry.
Area Of Science
- Hematology
- Oncology
- Molecular Diagnostics
Background
- Multiplex PCR and NGS identify neoplastic clonotypes for minimal residual disease (MRD) tracking.
- The utility of NGS for MRD detection in mixed phenotype acute leukemia (MPAL) remains uninvestigated.
Purpose Of The Study
- To investigate the feasibility and efficacy of NGS-based MRD tracking in patients diagnosed with MPAL.
Main Methods
- Retrospective chart review of MPAL patients identified via a cancer center database.
- Analysis of clonoSEQ data for clonotype identification and MRD assessment.
- Procurement of clinical data from electronic medical records.
Main Results
- Twenty-nine MPAL patients were identified; only two had clonoSEQ testing.
- Both patients exhibited a B/myeloid phenotype and bilineal disease.
- NGS (clonoSEQ) successfully identified dominant clonotypes and tracked MRD, correlating with clinical disease burden.
Conclusions
- This study provides the first evidence supporting the use of NGS for MRD monitoring in MPAL.
- NGS demonstrates superior sensitivity for MRD detection in MPAL compared to flow cytometry.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
